hoodb.com

北極星藥業-KY(6550)啟動向美國FDA呈送Pegargiminase(ADI-PEG 20) 生物製劑用於治療惡性肺間皮癌的上市許可證 ...

|

You are leaving and open the following URL" of about "adi" news

news.google.com/rss/articles/CBMiQGh0dHA6Ly93d3cuZ2VuZXRpbmZvLmNvbS9pbnZlc3RtZW50L2NvbXBhbnktbmV3cy9pdGVtLzc1MjM1Lmh0bWzSAQA?oc=5


Continue Opne >

adi: 北極星藥業-KY(6550)啟動向美國FDA呈送Pegargiminase(ADI-PEG 20) 生物製劑用於治療惡性肺間皮癌的上市許可證 ...


More adi news:


About adi

from

Warning: file_get_contents(aCache/search/th/adi): Failed to open stream: Permission denied in /var/www/hoodb/function.php on line 340

adi, 北極星藥業-KY(6550)啟動向美國FDA呈送Pegargiminase(ADI-PEG 20) 生物製劑用於治療惡性肺間皮癌的上市許可證 ... 2022 adi

北極星藥業-KY(6550)啟動向美國FDA呈送Pegargiminase(ADI-PEG 20) 生物製劑用於治療惡性肺間皮癌的上市許可證 ...

Choose Your Country or Region


Back to Top



北極星藥業-KY(6550)啟動向美國FDA呈送Pegargiminase(ADI-PEG 20) 生物製劑用於治療惡性肺間皮癌的上市許可證 ...

Copyright © 2020-2021 hoodb.com. All Rights Reserved.